Placental vascular compromise: Unifying the etiologic pathways of perinatal compromise

Current Problems in Obstetrics, Gynecology and Fertility

Volumn 24, Issue 6, 2001, Pages 201-220

  Van Le, L ^a   Thorp J M , Jr ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTINE; INSULIN;

AMINO ACID METABOLISM; ATHEROSCLEROSIS; BLOOD CLOTTING DISORDER; CHRONIC INFLAMMATION; DYSLIPIDEMIA; HISTOLOGY; HUMAN; INFECTION; INSULIN RESISTANCE; PATHOPHYSIOLOGY; PERINATAL CARE; PERINATAL PERIOD; PLACENTA CIRCULATION; PREGNANCY; PREMATURITY; REVIEW;

EID: 0035667549     PISSN: 87560410     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (298)

1. Conceptualizing categories of preterm birth
2. Epidemiologic characteristics of preterm delivery: Etiologic heterogeneity
3. The length of the cervix and the risk of spontaneous premature delivery
4. Cervical dimensions and risk of preterm birth: A prospective cohort study
5. Prevention of premature birth
6. Preterm delivery among black and white enlisted women in the United States Army
7. Maternal nutrition and spontaneous preterm birth
8. Etiologies of preterm birth in an indigent population: Is prevention a logical expectation?
9. Prevention of preeclampsia with low-dose aspirin in healthy nulliparous pregnant women
10. Low-dose aspirin to prevent preeclampsia in women at high risk
11. Current concepts of fetal growth restriction. Part I. Causes, classification, and pathophysiology
12. Causes of intrauterine growth retardation
13. Impaired fetal growth: Definition and clinical diagnosis
14. Low birth weight intrauterine growth retardation and preterm delivery
15. Intrauterine growth retardation and preterm delivery
16. Neonatal mortality risk in relation to birth weight and gestational age. Update
17. Growth retardation in preterm infants
18. Fetal morbidity following potentially anoxigenic obstetric conditions. Part I. Abruptio placentae
19. Incidence and recurrence rate of abruptio placentae in Sweden
20. Placental abruption and perinatal mortality in the United States
21. A history of placenta dysfunction and risk of placental abruption
22. Uterine blood flow in pregnancy: An overview
23. The relationship between acute inflammatory lesions of the preterm placenta and amniotic fluid microbiology
24. Clinical significance of increasing histologic severity of acute inflammation in the fetal membranes and umbilical cord
25. Placental pathology of preterm preeclampsia
26. Immunohistochemical study of the inflammatory infiltrate in villitis of unknown etiology. A qualitative and quantitative analysis
27. Immunohistologic evidence that villitis in human normal term placentas is an immunologic lesion
28. Increased placental antifibrinolytic potential and fibrin deposits in pregnancy-induced hypertension and preeclampsia
29. Apoptotic changes occur in syncytiotrophoblast of human placental villi where fibrin type fibrinoid is deposited at discontinuities in the villous trophoblast
30. An ultrastructural study of utero-placental spiral arteries in hypertensive and normotensive pregnancy and fetal growth retardation
31. The placental bed biopsy: Review from three European centers
32. Fetal growth retardation and the maternal arterial supply of the human placenta in the absence of sustained hypertension
33. The very low birthweight infant: Maternal complications leading to preterm birth, placental lesions, and intrauterine growth
34. Decidual arteriopathy in hypertension and diabetes in pregnancy: Immunofluorescent studies
35. Placental abruption in preterm gestation: An association with chorioamnionitis
36. Choriodecidual inflammation: A potentially preventable cause of perinatal HIV-1 transmission?
37. Preterm labor: Emerging role of genital tract infections
38. The preterm prediction study: Fetal fibronectin, bacterial vaginosis and peripartum infection
39. Ampicillin and metronidazole treatment in preterm labour: A multicentre, randomised controlled trial
40. Acute chorioamnionitis and duration of membrane rupture correlates with vertical transmission of HIV-1
41. Infectious diseases
42. Neutrophil structure and function
43. Stimulated polymorphonuclear leukocytes in vaginal secretions from patients with preterm labor
44. Polymorphonuclear leukocytes in the fetal membranes are activated in patients with preterm delivery: Ultrastructural and enzyme-histochemical evidence
45. Infection and preterm labor III. Interleukin-I: A signal for the onset of parturition
46. Amniotic fluid interleukin 6 in preterm labor
47. Infection and preterm labor. IV. Cathectintumor necrosis factor in the amniotic fluid of women with intraamniotic infection and preterm labor
48. Interleukin (IL)-6 and IL-8 production by human amnion: Regulation by cytokines growth factors, glucocorticoids, phorbol esters, and bacterial lipopolysaccharide
49. Interleukin-6 stimulates prostaglandin production by human amnion and decidual cells
50. Intestinal collagen synthesis and processing in human amnion: A property of the mesenchymal cells
51. Atherosclerosis-an inflammatory disease
52. Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis
53. The pathogenesis of atherosclerosis
54. The pathogenesis of atherosclerosis - An update
55. The pathogenesis of atherosclerosis: A perspective for the 1990s
56. Atherosclerosis: A defense mechanism gone awry
57. Inflammation, infection, and cardiovascular risk: How good is the clinical evidence?
58. Molecular basis of the acute coronary syndromes
59. Inflammation in acute coronary syndromes
60. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology
61. Influx of neutrophils into the walls of large epicardial coronary arteries in response to ischemia/reperfusion
62. Macrophage infiltration in acute coronary syndromes: Implications for plaque rupture
63. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques
64. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis
65. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
66. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
67. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina
68. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group
69. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study
70. Production of C-reactive protein and risk of coronary events in stable and unstable angina
71. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men
72. Roles of infectious agents in atherosclerosis and restenosis: An assessment of the evidence and need for future research
73. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade II atherosclerosis
74. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: Evaluation of the innocent bystander hypothesis
75. Chlamydia pneumoniae in atheroma: Consideration of criteria for causality
76. Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease
77. Cytomegalovirus and atherosclerosis
78. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction
79. Chronic infection with Helicobacter pylori, Chlamydia pneumoniae, or cytomegalovirus: Population based study of coronary heart disease
80. Virus-induced atherosclerosis: Herpes virus infection alters aortic cholesterol metabolism and accumulation
81. Herpes viruses in atherosclerosis and thrombosis: Etiologic agents or ubiquitous bystanders?
82. Antibiotics for prevention of myocardial infarction? Not yet!
83. Randomised trial of roxithromycin in non-Q-wave coronary syndromes. ROXIS pilot study
84. Antibiotics and risk of subsequent first-time acute myocardial infarction
85. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model
86. Sexually transmitted diseases in pregnancy
87. The silent epidemic of Chlamydia trachomatis: The urgent need for detection and treatment in women
88. Update on Chlamydia trachomatis
89. The controversy surrounding indomethacin for tocolysis
90. The cell adhesion molecule, VCAM-1, is selectively elevated in serum in pre-eclampsia: Does this indicate the mechanism of leucocyte activation?
91. Serum from preeclamptic women induces vascular cell adhesion molecule-1 expression on human endothelial cells in vitro: A possible role of increased circulating levels of free fatty acids
92. Immunoendocrinology of preterm labor: The link between corticotropin-releasing hormone and inflammation
93. The interleukin-1 family: 10 years of discovery
94. Maternal second trimester serum tumor necrosis factor-α-soluble receptor p55 (sTNFp55) and subsequent risk of preeclampsia
95. The tumor necrosis family ligand and receptor families
96. Chemokines: Leucocyte recruitment and activation cytokines
97. 2 on the human cervix: Stimulation of interleukin 8 and inhibition of secretory leukocyte protease inhibitor
98. Infection and labor. III. Interleukin-1: A signal for the onset of labor
99. Tumor necrosis factor in preterm and term labor
100. Clinical value of amniotic fluid interleukin-6 determinations in the management of preterm labor
101. Neutrophil attractant/activating peptide-1 interleukin-8 in term and preterm parturition
102. Elevations of amniotic fluid macrophage inflammation protein-1α concentrations in women during term and preterm labor
103. Elevation of amniotic fluid interleukin-1 concentrations in women with preterm labor and chorioamnionitis
104. Human decidua: A source of interleukin-1
105. Cachectin/tumor necrosis factor-α formation in the human decidua: Potential role of cytokines in infection-induced preterm labor
106. Decidual cell biosynthesis of interleukin-6: Regulation by inflammatory cytokines
107. Inflammatory mediators regulate IL-8 production by cultured gestational tissues: Evidence for a cytokine network at the chorio-decidual interface
108. Regulation of human decidual cell macrophage inflammatory protein-1α (MIP-1α) by inflammatory cytokines
109. Regulation of decidual cell chemokine production by group B streptococci and purified bacterial cell wall components
110. Biosynthesis of interleukin-6 by cultured human chorion laeve cells: Regulation by cytokines
111. Regulation of cultured human chorion cell chemokine production by group B streptococci and purified bacterial products
112. Prostaglandins and parturition
113. The mouse as an investigational model for preterm labor
114. A rabbit model for bacteria-induced preterm pregnancy loss
115. An experimental model for intraamniotic infection and preterm labor in rhesus monkeys
116. Tumor necrosis factor-alpha is elevated in plasma and amniotic fluid of patients with severe preeclampsia
117. Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with preeclampsia
118. Bioactive tumour necrosis factor α in pre-eclamptic patients with and without the HELLP syndrome
119. Tumor necrosis factor: Characterization at the molecular, cellular and in vivo level
120. Evidence for an elevation in serum interleukin-2 and tumor necrosis factor-α levels before the clinical manifestations of preeclampsia
121. Cytokine measurements and interpretation of cytokine assays in human disease
122. Chemical and biological characterization of corticotropin releasing factor
123. Putative role of placental corticotropin-releasing factor in the mechanisms of human parturition
124. Corticotropin releasing factor-like activity in human placental extracts
125. Isolation and characterization of a corticotropin-releasing hormone-like peptide from human placenta
126. Corticotrophin releasing hormone- and adreno-corticotropin-like immunoreactivity in human placenta, peripheral and uterine vein plasma
127. Characterization and gestational regulation of corticotropin-releasing hormone messenger RNA in human placenta
128. The corticotropin releasing hormone gene is expressed in human placenta
129. Evidence for local stimulation of ACTH secretion by corticotropin-releasing factor in human placenta
130. Corticotropia releasing factor in human placenta: Localization, concentration and release in vitro
131. The localization and distribution of corticotropin-releasing hormone in the human placenta and fetal membranes throughout gestation
132. Steroids modulate corticotropin-releasing hormone production in human fetal membranes and placenta
133. Corticotropin-releasing hormone production by the placenta and fetal membranes
134. Glucocorticoid stimulates expression of corticotropin-releasing hormone gene in human placenta
135. Cloning and characterization of the cDNAs for human and rat corticotropin releasing factor-binding proteins
136. The central distribution of a corticotropin releasing factor-binding protein predicts multiple sites and mode of interaction with CRF
137. Corticotropin-releasing factor-binding protein is produced by human placenta and intrauterine tissues
138. Current topic: The placental corticotropin releasing hormone-adreno-corticotrophin axis
139. A specific carrier substance for human corticotropin releasing factor in late gestational maternal plasma which could mask the ACTH releasing activity
140. Specific high affinity binding protein for human corticotropin releasing hormone in normal human plasma
141. Presence of CRF-binding protein in amniotic fluid and in umbilical cord plasma
142. Plasma corticotropin releasing hormone, β endorphin and cortisol inter relationship during human pregnancy
143. Pulsatile fluctuations of plasma-gonadotropin-releasing hormone and corticotropin-releasing factor levels in healthy pregnant women
144. Plasma corticotropin releasing hormone concentrations during pregnancy and parturition
145. Circulating maternal corticotropin-releasing hormone and gonadotropin-releasing hormone in normal and abnormal pregnancies
146. The nonsuppressibility of plasma cortisol persists after pregnancy
147. Corticotropin-releasing factor and parturition: Plasma and amniotic fluid levels and placental binding sites
148. Biologically active corticotropin-releasing hormone in maternal and fetal plasma during pregnancy
149. Human corticotropin-releasing hormone during pregnancy
150. Relationship between maternal and fetal corticotropin releasing hormone-41 and ACTH levels in human mid-trimester pregnancy
151. Corticotropin releasing hormone-binding protein: Plasma levels decrease during the third trimester of normal human pregnancy
152. Plasma measurements of corticotropin-releasing hormone-binding protein in normal and abnormal human pregnancy
153. Cord plasma corticotropin-releasing factor (CRF) are inversely correlated with low levels of maternal CRF-binding protein in pregnant women with pregnancy-induced hypertension
154. Placental corticotrophin releasing factor may modulate human parturition
155. Role of prostaglandins and leukotrienes in the synergistic effect of oxytocin and corticotropin-releasing hormone (CRH) on the contraction force in human gestational myometrium
156. Local stimulation of prostaglandin production by corticotropin-releasing hormone in human fetal membranes and placenta
157. Effects of corticotropin-releasing hormone and adrenocorticotropin on prostaglandin output by human placenta and fetal membranes
158. Steroid, corticotropin releasing hormone, ACTH and prostaglandin interaction in the amnion and placenta of early pregnancy in man
159. Activin A, corticotropin-releasing factor and prostaglandin F2 alpha increase immuno-reactive oxytocin release from cultured human placental cells
160. Maternal corticotropin-releasing hormone is increased with impending preterm birth
161. A placental clock controlling the length of human pregnancy
162. Cord plasma corticotropin-releasing factor-binding protein (CRF-BP) in term and preterm labour
163. Maternal plasma immunoreactive corticotropin releasing factor levels in infection-associated term and preterm delivery
164. Maternal plasma corticotropin releasing hormone is elevated in preterm labour but unaffected by indomethacin or nylidrin
165. Corticotropin-releasing hormone in maternal and cord plasma in pre-eclampsia
166. Corticotrophin releasing hormone binding protein in normal and pre-eclamptic human pregnancy
167. Hypotensive effect of ovine and human corticotropin releasing factors in man
168. Plasma corticotropin releasing factor in abnormal pregnancy
169. Abnormal umbilical artery Doppler waveforms and cord blood corticotropin-releasing hormone
170. The effect of pre-eclampsia on human placental corticotrophin releasing hormone content and processing
171. 2 in the sheep fetus during late pregnancy
172. Interleukin-1 stimulates the secretion of hypothalamic corticotrophin releasing factor
173. Synthesis of interleukin-1/endogenous pyrogen in the brain of endotoxin-treated mice: A step in fever induction?
174. Interactions between tumor necrosis factor-α, hypothalamic corticotrophin-releasing hormone, and adrenocorticotropin secretion in the rat
175. Immunosuppressive activity of corticotrophin-releasing factor
176. Effect of the corticotrophin releasing hormone precursor on interleukin-6 release by human mononuclear cells
177. A molecular mechanism for stress-induced alterations in susceptibility to disease
178. Long-term intracerebroventricular infusion of corticotrophin-releasing hormone alters neuroendocrine, neurochemical, autonomic, behavioral and cytokine responses to a systemic inflammatory challenge
179. Long-term intracerebroventricular corticotrophin-releasing hormone administration induces distinct changes in rat splenocyte activation and cytokine expression
180. Changes in homocysteine levels during normal pregnancy
181. Clinical chemistry and molecular biology of homocysteine metabolism: An update
182. Intermediate homocysteinemia: A thermolabile variant of methylenetetrahydrofolate reductase
183. Improved identification of heterozygotes for homocysteine synthase deficiency by the combination of methionine loading and enzyme determination in cultured fibroblasts
184. Homocysteine species as components of plasma redox thiol status
185. Vitamin B12, vitamin B6, and folate nutritional status in men with hyperhomocysteinemia
186. Hyperhomocysteinemia and the response to vitamin supplementation
187. Reduction of plasma homocysteine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease
188. Effects of folic acid and vitamin B6 supplementation on women with hyperhomocysteinemia and a history of preeclampsia or fetal growth restriction
189. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis
190. Association between plasma homocysteine concentrations and extracranial carotidartery stenosis
191. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation
192. Adverse vascular effects of homocysteine are modulated to endothelium-derived relaxing factor and related oxides of nitrogen
193. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathionine peroxidase
194. Activation of Hageman factor by L-homocysteine
195. Activation of endogenous factor V by a homocysteine-induced endothelial cell activator
196. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells
197. Hyperhomocys-teinemia and atherothrombosis
198. Fasting serum triglycerides, free fatty acids, and malondialdehyde are increased in preeclampsia, are positively correlated, and decrease within 49 hours postpartum
199. Fasting serum free fatty acids and triglycerides are increased before 20 weeks of gestation in women who later develop preeclampsia
200. Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia
201. Preeclampsia: An endothelial cell disorder
202. Plasma Homocysteine levels elevated and inversely related to insulin sensitivity in preeclampsia
203. Hyperhomocysteinemia: A risk factor for placental abruption or infarction
204. Hyperhomocysteinemia: A risk factor in women with unexplained recurrent early pregnancy loss
205. Underlying disorders associated with severe early-onset preeclampsia
206. Elevated homocyst(e)ine levels with preeclampsia
207. The pathogenesis of atherosclerosis: A perspective for the 1990s
208. Metabolic risk factors for coronary artery disease in women: Prospective from the Framingham Study
209. Heterogeneity of serum low density lipoproteins in normal human subjects
210. Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women
211. Change in LDL particle size is associated with changes in plasma triglyceride concentration
212. Gradient gel electrophoresis of human plasma lipoproteins
213. Genetic, metabolic, and dietary influences on the atherogenic lipoprotein phenotype
214. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans
215. The hyperlipidemia of pregnancy in normal and complicated pregnancies
216. Hypertriglyceridemia during late pregnancy is associated with the formulation of small dense low-density lipoproteins and the presence of large buoyant high-density lipoproteins
217. Low-density lipoprotein particle size decreases during normal pregnancy in association with triglyceride increases
218. Longitudinal study on lipoprotein profile, high-density lipoprotein subclass, and postheparin lipases during gestation in women
219. Lipoprotein metabolism in pregnancy
220. The role of the placenta in lipid metabolism and transport
221. Lipoprotein subfraction concentrations in preeclampsia: Pathogenic parallels to atherosclerosis
222. Higher cholesterol and insulin levels in pregnancy are associated with increased risk for pregnancy-induced hypertension
223. Fasting serum free fatty acids and triglycerides are increased before 20 weeks of gestation in women who later develop preeclampsia
224. A controlled study of maternal serum concentrations of lipoproteins in pregnancy-induced hypertension
225. Insulin response to oral glucose in patients with preeclampsia
226. Pre-eclampsia and eclampsia associated with increased lipid peroxidation and decreased serum vitamin E levels
227. Increased contents of phospholipids, cholesterol, and lipid peroxides in decidua basalis in women with preeclampsia
228. Studies on the role of lipoperoxides in human pathology: The presence of peroxidized lipids in the atherosclerotic aorta
229. Lipid peroxidation in pregnancy
230. Longitudinal changes in insulin resistance in non-obese pregnancy women
231. A longitudinal study of carbohydrate metabolism in healthy, obese pregnant women
232. Correlation of hormones with lipid and lipoprotein levels during normal pregnancy and postpartum
233. Impaired endothelium-dependent vasodilatation in women with previous gestational diabetes
234. The pathogenesis of GDM: Implication for diabetes after pregnancy
235. NIDDM and GDM: Same disease, another name?
236. The changing faces of macrovascular disease in non-insulin dependent diabetes mellitus: An epidemic in progress
237. Prognosis of the outcome of pregnancies in diabetics: A new classification
238. Preeclampsia in diabetic pregnancies
239. Outcome of pregnancies complicated by type 1 insulin dependent diabetes in Sweden: Acute pregnancy complication, neonatal mortality and morbidity
240. Pregnancy complications among diabetic women: Review 1965-1985
241. Hypertension during pregnancy in insulin-dependent diabetic women
242. Epidemiology of pregnancy-induced hypertension and preeclampsia in Type 1 (insulin-dependent) diabetic pregnancies in Sweden
243. Longitudinal study of plasma lipoproteins and hormones during pregnancy in normal and diabetic women
244. Free fatty acids and insulin resistance during pregnancy
245. The lipolytic action of human placental lactogen in isolated fat cells
246. Perspectives in diabetes: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM
247. Mechanism for the stimulation of gluconeogenesis by fatty acids in perfused rat liver
248. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss
249. Mutation in blood coagulation factor V associated with resistance to activated protein C
250. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
251. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis
252. Resistance to activated protein C as a basis for venous thrombosis
253. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study
254. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men
255. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism
256. The risk of recurrent venous thromboembolism in patients with an Art506-G1n mutation in the gene for factor V (factor V Leiden)
257. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women
258. Resistance to activated protein C: A common anticoagulant deficiency in patients with venous leg ulceration
259. Activated protein C resistance, factor V Leiden and peripheral vascular disease
260. Reduced response to activated protein C is associated with an increased risk for cerebrovascular disease
261. Interrelation of hyperhomocysteinemia, factor V Leiden, and risks of future venous thromboembolism
262. Increased risk of venous thrombosis in oralcontraceptive users who are carriers of factor V Leiden mutation
263. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation
264. Factor V Leiden mutation and the risks for thromboembolic disease: A clinical perspective
265. Ethnic distribution of factor V Leiden in 4047 men and women: Implications for venous thromboembolism screening
266. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia
267. Genetic susceptibility to pregnancy-related venous thromboembolism: Roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations
268. Coexistence of hereditary homocystinuria and factor V Leiden: Effect on thrombosis
269. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
270. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia
271. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease
272. The 20210A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis
273. The prothrombin gene G20210A variant: Prevalence in a UK anticoagulant clinic population
274. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3'-untranslated region of the prothrombin gene
275. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women
276. The prevalence of the 20210 G-A mutation in the 3'-untranslated region of the prothrombin gene in patients with premature coronary artery disease
277. Interaction of coagulation defects and cardiovascular risk factors: Increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A
278. Risk of stroke in young women and two prothrombotic mutations: Factor V Leiden and prothrombin gene variant (G20210A)
279. Final report of the aspirin component of the ongoing Physicians' Health Study
280. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men
281. Increased frequency of genetic thrombophilia in women with complications of pregnancy
282. Thrombophilias and adverse outcomes of pregnancy - What should a clinician do?
283. Effects of folic acid and vitamin B6 supplementation on women with hyperhomocysteinemia and a history of preeclampsia or fetal growth restriction
284. Increased fetal loss in women with heritable thrombophilia
285. Factor V Leiden, C, ÆT MTHFR polymorphism and genetic susceptibility to preeclampsia
286. The factor V Leiden mutation may predispose women to severe preeclampsia
287. Resistance to activated protein C and the Leiden mutation: High prevalence in patients with abruptio placentae
288. HELP syndrome associated with factor V R506Q mutation
289. Preeclampsia is associated with a reduced response to activated protein C
290. Activated protein C resistance and adverse pregnancy outcome
291. Activated protein C resistance and pregnancy complications
292. Preeclampsia: An endothelial cell disorder
293. Placental pathologic features of preterm preeclampsia
294. Ultrastructural aspects of preeclampsia. I. Placental bed and uterine boundary vessels
295. Acute atherosis in preeclampsia: Maternal determinants and fetal outcome in the presence of the lesion
296. Intrauterine growth restriction in infants of less than thirty-two weeks' gestation: Associated placental pathologic features